摘要: Abstract Graft-versus-host disease (GVHD) is a serious complication that occurs after allogeneic bone marrow transplantation and contributes to transplant-related morbidity mortality. Recent advances in the measurement of recipient-specific alloreactivity before grafting have led development vitro assays sufficiently predict occurrence moderate severe acute GVHD. This predicative information provides basis for attempts minimize, or prevent, GVHD by prospective donor selection individualized immunotherapeutic strategies.